Status:

COMPLETED

Premium Trifocal IOL Comparative Analysis

Lead Sponsor:

Beaver-Visitec International, Inc.

Conditions:

Cataract

Lens Opacities

Eligibility:

All Genders

45+ years

Phase:

NA

Brief Summary

Short and long-term analysis of the refraction correction and optical image quality of modern premium intraocular lenses (IOLs) with the establishment of a database for quality assurance and optimizat...

Detailed Description

Since the investigational lens, like conventional IOLs, is a posterior chamber lens which is widely implanted following cataract extraction, phacoemulsification is adopted. To assess the binocular vis...

Eligibility Criteria

Inclusion

  • Inclusion criteria
  • Availability, willingness and sufficient cognitive awareness to comply with examination procedures
  • Bilateral implantation of one of the following IOL models
  • Alcon PanOptix (TFNT00)
  • PhysIOL FineVision (POD F)
  • PhysIOL FineVision (POD F GF)
  • Uneventful cataract surgery with first clinical outcomes in the expected range
  • Patient included in Premium IOL study protocol by signed informed consent
  • Exclusion criteria
  • Age of patient \<45 years
  • Irregular astigmatism
  • Postoperative manifested astigmatism of \>1.0 D
  • Difficulty for cooperation (distance from their home, general health condition)
  • Clinically significant glaucoma
  • Clinically significant macular degeneration, clinically significant macular edema or proliferative diabetic retinopathy
  • Patients with keratoconus or keratectasia
  • Any ocular comorbidity having a significant effect on the postoperative clinical outcomes
  • History of ocular trauma or prior ocular surgery including refractive procedures
  • Capsule or zonular abnormalities that may affect postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome, chronic Uveitis, Marfan's syndrome)
  • Pupil abnormalitis (non-reactive, tonic pupils, abnormally shaped pupils or pupils that do not dilate under mesopic/scotopic conditions)
  • AMD
  • Intraoperative complications like capsular rupture etc.
  • Patients who do not give informed consent

Exclusion

    Key Trial Info

    Start Date :

    November 1 2017

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    November 17 2021

    Estimated Enrollment :

    133 Patients enrolled

    Trial Details

    Trial ID

    NCT04875455

    Start Date

    November 1 2017

    End Date

    November 17 2021

    Last Update

    January 11 2022

    Active Locations (4)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (4 locations)

    1

    Augenklinik Ahaus

    Ahaus, Germany, 48683

    2

    Internationale Innovative Ophthalmochirgie

    Düsseldorf, Germany, 40212

    3

    Universitäts-Augenklinik Heidelberg

    Heidelberg, Germany, 69120

    4

    Augentagesklinik Rheine

    Rheine, Germany, 48429